Výsledky vyhledávání - "Manual Afable"

Deletions of Xp22.2 including PIG-A locus lead to paroxysmal nocturnal hemoglobinuria

Autor: Jaroslaw P. Maciejewski, David J. Araten, Michael J. Clemente, P.K. Epling-Burnette, Manual Afable, Alan F. List, Kenneth H. Shain, Chiharu Sugimori, Christine L. O'Keefe

Publikováno v: Leukemia. 25(2)

1158 Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired hematopoietic stem cell disorder characterized by a global deficiency of glycosylphospatidyl inositol-floated proteins (GPI-AP) on the membrane of all cell types derived from the affected

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4ea859038309a30e09f5cf3781b51a78
https://pubmed.ncbi.nlm.nih.gov/21116280

Zobrazit plný text záznamu

Final Results From the Phase 2 Continuation Study of the Lenalidomide and Azacitidine Combination in Patients with Higher-Risk Myelodysplastic Syndromes (MDS)

Autor: Rami S. Komrokji, Anjali S. Advani, Lori Strozniak, Ricki Englehaupt, Alan F. List, Jennifer Paleveda, David Cuthbertson, Joyce Juersivich, Jeffrey E. Lancet, Ronald Paquette, Mikkael A. Sekeres, Ramon V. Tiu, Jaroslaw P. Maciejewski, Manual Afable, April Smith

Publikováno v: Blood. 118:607-607

Abstract 607 Background: Lenalidomide (LEN) and azacitidine (AZA) have activity in lower- and higher-risk MDS patients (pts), where both microenvironment and cell regulatory mechanisms play a role. The LEN/AZA combination was well-tolerated in the Ph

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::bca2785ac7b168e7162a0786c72d74f5
https://doi.org/10.1182/blood.v118.21.607.607

Zobrazit plný text záznamu

A Proof of Principle Clinical Trial in Myelodysplastic Syndromes of Non-Cytotoxic Differentiation Therapy with Decitabine

Autor: Eric D. Hsi, Ricki Englehaupt, Lisa Durkin, Matt Kalaycio, Edward A. Copelan, Manual Afable, Yogen Saunthararajah, Joy Juersivich, Kathleen Cooper, Jaroslaw P. Maciejewski, Anjali S. Advani, Mikkael A. Sekeres, Ronald Sobecks, Tomas Radivoyevitch, Reda Z. Mahfouz, Robert M. Dean

Publikováno v: Blood. 118:3830-3830

Abstract 3830 In myeloid malignancies, genetic abnormalities in key apoptosis pathway genes (eg., p53) are associated with poor responses to conventional cytotoxic therapy. In pre-clinical models, non-cytotoxic, DNA methyltransferase 1 (DNMT1) deplet

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::25512dd23d777a30e124c2c11790b58a
https://doi.org/10.1182/blood.v118.21.3830.3830

Zobrazit plný text záznamu

Deletions of Xp22.2 Including PIG-A Locus Lead to Paroxysmal Nocturnal Hemoglobinuria

Autor: P.K. Epling-Burnette, David J. Araten, Kenneth H. Shain, Christine L. O'Keefe, Michael J. Clemente, Chiharu Sugimori, Jaroslaw P. Maciejewski, Manual Afable, Alan F. List

Publikováno v: Blood. 116:1158-1158

Abstract 1158 Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired hematopoietic stem cell disorder characterized by a global deficiency of glycosylphospatidyl inositol-floated proteins (GPI-AP) on the membrane of all cell types derived from the

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c282362e1327da4fa1a658aef9fbda76
https://doi.org/10.1182/blood.v116.21.1158.1158

Zobrazit plný text záznamu

Prior Therapy with DNA Methyltransferase Inhibitors (DNMTI) Predicts for Lower Remission Rates and Worse Survival In Secondary Acute Myeloid Leukemia Patients (sAML) Receiving Remission Induction Therapy

Autor: Katarina Paulic, Sanjay R. Mohan, Marc Earl, Ronald Sobecks, Ricki Englehaupt, Mikkael A. Sekeres, Matt Kalaycio, Anjali S. Advani, Edward A. Copelan, Ramon V. Tiu, Jaroslaw P. Maciejewski, Manual Afable, Yogen Saunthararajah, Alex Z. Fu

Publikováno v: Blood. 116:4033-4033

Abstract 4033 Background: DNMTIs are the most commonly used disease modifying agents for myelodysplastic syndromes (MDS), particularly in patients (pts) with higher-risk MDS. Many will subsequently develop acute myeloid leukemia (AML) and will be tre

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::2d5179112793f64e3473147b2a1099b8
https://doi.org/10.1182/blood.v116.21.4033.4033

Zobrazit plný text záznamu

Final Results from a Phase I Combination Study of Lenalidomide and Azacitidine in Patients with Higher-Risk Myelodysplastic Syndromes (MDS)

Autor: Katarina Paulic, David Cuthbertson, Mikkael A. Sekeres, Ronald Paquette, Jaroslaw P. Maciejewski, Alan F. List, Thomas P. Loughran, Manual Afable, Deborah Latham

Publikováno v: Blood. 112:221-221

Background: Lenalidomide (LEN) and azacitidine (AZA) have demonstrated single agent activity in lower- and higher-risk MDS patients (pts). Response rates may be improved by combining LEN’s immunomodulatory, anti-angiogenic, and cytotoxic properties

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f103bdd18fcad0bce1bd067448d23863
https://doi.org/10.1182/blood.v112.11.221.221

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání